Efficacy of IV tissue plasminogen activator in acute stroke: Does stroke subtype really matter?

Neurology

Volumn 61, Issue 1, 2003, Pages 71-75

  Hsia, A W ^a   Sachdev, H S ^b   Tomlinson, J ^b   Hamilton, S A ^a   Tong, D C ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b Good Samaritan Hospital San Jose   (United States)

^c Stanford California and Cofounder   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE;

EID: 0038691956     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000071228.56362.36     Document Type: Article

References (17)

1. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Madden KP, Karanjia PN, Adams HP, Clarke WR, the TOAST Investigators. Accuracy of initial stroke subtype diagnosis in the TOAST study. Neurology 1995;45:1975-1979.
3. Caplan LR, Mohr JP, Kistler JP, Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - not a panacea for ischemic stroke. N Engl J Med 1997;337:1309-1310, 1313.
4. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH Stroke Scale score from medical records. Stroke 1999;30:1534-1537.
5. Candelise L, Pinard G, Aritzu E, Musicco M. Telephone interview for stroke outcome assessment. Cerebrovasc Dis 1994;4:341-343.
6. Shinar D, Gross CR, Bronstein KS, et al. Reliability of the activities of daily living scale and its use in telephone interview. Arch Phys Med Rehabil 1987;68:723-728.
7. Korner-Bitensky N, Wood-Dauphinee S, Siemiatycki J, et al. Health-related information post-discharge: telephone versus face-to-face interviewing. Arch Phys Med Rehabil 1994;75:1287-1296.
8. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993;24:35-41.
9. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Generalized efficacy of rt-PA for acute stroke. Subgroup analysis of the NINDS rt-PA stroke trial. Stroke 1997;28:2119-2125.
10. Grotta J. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? rt-PA - the best current option for most patients. N Engl J Med 1997;337:1310-1313.
11. Kirshner HS. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? N Engl J Med 1998;338:761-763.
12. Mohr JP. Thrombolytic therapy for ischemic stroke: from clinical trials to clinical practice. JAMA 2000;283:1189-1191.
13. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-2605.
14. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology 2000;55:1649-1655.
15. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-1787.
16. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-2011.
17. Executive Committee of the American Society of Interventional and Therapeutic Neuroradiology. Intraarterial thrombolysis: ready for prime time? AJNR 2001;22:55-58.